PFD Capital Partners announced that portfolio company Regeneration Biomedical, Inc. presented newly reported clinical findings at the ISCT 2026 Annual Meeting in Dublin, Ireland, highlighting its direct-to-brain regenerative therapy platform for Alzheimer’s disease and other neurodegenerative conditions. The release focuses on completed Phase I findings showing reductions and normalization trends in Alzheimer’s-related biomarkers, including CSF phosphorylated tau, CSF total tau, amyloid PET centiloid scores, inflammatory proteomic markers, and exploratory cognitive measures, with certain biomarker improvements reportedly persisting through 52 weeks after a single treatment. PFD also emphasized its ongoing support of Regeneration Biomedical, including its prior equity position and expanded commitment of up to $25 million to support Phase 2A clinical development, positioning RBI’s platform as a potentially differentiated regenerative approach while reinforcing PFD’s broader strategy of combining medical receivables finance with selective investment in emerging healthcare innovation.